Gillian Murphy

Cancer Research · 2000–2011

A researcher in the Science corpus: 12 papers; trusts 9 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

• Cancer Research — 44 citations into it; #303 of 1,780 by trust here, #440 by citations
• Molecular Biology — 40 citations into it; #5,676 of 17,773 by trust here, #6,028 by citations
• Oncology — 34 citations into it; #275 of 1,698 by trust here, #464 by citations
• Hematology — 16 citations into it; #100 of 225 by trust here, #68 by citations
• Pulmonary and Respiratory Medicine — 5 citations into it

Whom Gillian Murphy trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Hideaki Nagase
2. R. Visse
3. A. Newby
4. K. Brew
5. A. Baker
6. Zena Werb
7. Ralph Weissleder
8. M. Egeblad
9. D. Edwards
10. W. Parks

Who trusts Gillian Murphy overall

1. R. Khalil
2. S. Zhong
3. Xi Wang
4. Hideaki Nagase
5. Soo-Hyun Kim
6. K. Brew
7. M. Xue
8. D. Edwards

Papers from Gillian Murphy's perspective

Ordered by how strongly the researchers Gillian Murphy trusts endorse each paper. Same corpus, a different order for every researcher.

1. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
2. How matrix metalloproteinases regulate cell behavior. (Annual Review of Cell and Developmental Biology)
3. TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)*
4. New functions for the matrix metalloproteinases in cancer progression (Nature Reviews. Cancer)
5. Tissue inhibitors of metalloproteinases: evolution, structure and function. (Biochimica et Biophysica Acta)
6. S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death (Science)
7. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. (Journal of Clinical Investigation)
8. Matrix metalloproteinases and the regulation of tissue remodelling (Nature reviews. Molecular cell biology)
9. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. (Cell)
10. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice (Development)

Their papers

• Structure and function of matrix metalloproteinases and TIMPs. (2006) — 3,321 citations
• Evidence for a Critical Role of the Tumor Necrosis Factor α Convertase (TACE) in Ectodomain Shedding of the p75 Neurotrophin Receptor (p75NTR)* (2004) — 160 citations
• The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. (2008) — 45 citations
• Tissue inhibitors of metalloproteinases (2011) — 473 citations
• Progress in matrix metalloproteinase research. (2008) — 743 citations
• Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2) (2010) — 39 citations
• ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking (2005) — 257 citations
• A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2 (2003) — 681 citations
• ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. (2002) — 239 citations
• The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs (2002) — 148 citations
• Metalloproteinase inhibitors: biological actions and therapeutic opportunities (2002) — 1,206 citations
• Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* (2000) — 233 citations